Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10044552HBVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS10052789HBVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS30073184HIVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS44024288HTLV-1ENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TCGA Plot Options
Drug Information
GeneAR
DrugBank IDDB15647
Drug NameKetodarolutamide
Target IDBE0000132
UniProt IDP10275
Regulation Typeantagonist
PubMed IDs26137992; 26313416; 28490267
CitationsMoilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykanen PS, Tormakangas OP, Palvimo JJ, Kallio PJ: Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007.@@Fizazi K, Albiges L, Loriot Y, Massard C: ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015;15(9):1007-17. doi: 10.1586/14737140.2015.1081566.@@Shore ND: Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017 Jun;18(9):945-952. doi: 10.1080/14656566.2017.1329820. Epub 2017 May 24.
GroupsExperimental
Direct Classification
SMILESC[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)=O
Pathways
PharmGKB
ChEMBL